Partial
Needs Revision
Patient Risk:
Moderate
Summary
The response correctly recognizes that most quantitative, comparative, subgroup, intervention, and mechanistic weight-gain claims are absent from the supplied label excerpts. However, it introduces unsupported content from label sections not supplied, incorrectly states that Section 5.5 contains weight-monitoring language, and treats an unsupported adolescent claim as merely absent rather than addressing the supplied pediatric-use limitation.
Category Scores
Accurate Statements
Most unsupported comparative weight claims were correctly identified as absent from the supplied PERSERIS label sections.
The supplied sections do not provide comparisons with olanzapine, clozapine, aripiprazole, ziprasidone, quetiapine, or switching and adjunctive-treatment recommendations.
The claim that risperidone elevates prolactin levels is supported by Section 5.6.
Section 5.6 states that risperidone elevates prolactin levels and that the elevation persists during chronic administration.
The claim regarding steady subcutaneous release should be treated cautiously.
Sections 11 and 12.3 support extended-release subcutaneous administration and pharmacokinetic steady-state findings, but do not expressly state 'steady subcutaneous release.'
The adolescent weight-gain incidence estimate is not supported by the supplied label.
Section 8.4 states that safety and effectiveness of PERSERIS have not been established in pediatric patients.
Unsupported Statements
The indication is in Section 1, and dosage and administration are in Section 2.
Sections 1 and 2 were not supplied, so these section-content assertions cannot be verified against the provided prescribing information.
The response omitted the boxed warning, contraindication, dosing, pregnancy, and major-warning information identified in Sections 1, 2, 4, 5.1–5.14, and 8.1–8.2.
Those sections and their contents were not included in the supplied label excerpts. Their asserted contents are therefore unsupported for this audit.
PERSERIS is administered once monthly at 90 mg or 120 mg, requires prior oral risperidone tolerability, and is not interchangeable milligram-for-milligram with other injectable risperidone products.
These dosage and administration details are not present in the supplied sections.
Contradictions
Moderate
AI Statement
Section 5.5 includes monitoring language for metabolic changes, including monitoring weight.
Label Reference
Section 5.5 supplied text describes hyperglycemia, dyslipidemia, and body-weight gain but contains no weight-monitoring instruction.
Important Omissions
The response did not explicitly state that the evaluation is limited to the label sections supplied in the prompt and that unavailable sections cannot be used to establish additional omissions.
Importance:
High
The response did not clearly distinguish claims that are unsupported from claims that directly contradict the supplied label; this is particularly relevant to the adolescent claim.
Importance:
Moderate
The response did not identify that the supplied Section 8.4 specifically establishes that pediatric safety and effectiveness have not been established, which is material to evaluating the adolescent statement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response is primarily a meta-audit and does not directly prescribe treatment, but its unsupported assertions about unavailable warnings, contraindications, dosing, and monitoring could mislead users about what is established by the supplied label. The incorrect statement about Section 5.5 monitoring language is a material label-alignment error.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
The response relies on prescribing-information sections and content not supplied in the prompt and incorrectly attributes weight-monitoring requirements to Section 5.5.
Suggested Improvement
Restrict the audit to the supplied sections, remove assertions about unavailable sections, state that Section 5.5 does not specify monitoring in the provided excerpt, and characterize the adolescent claim as unsupported or not established rather than directly contradicted.